HUP0102187A2 - Azolo-triazinok és -pirimidinek, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása - Google Patents

Azolo-triazinok és -pirimidinek, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása

Info

Publication number
HUP0102187A2
HUP0102187A2 HU0102187A HUP0102187A HUP0102187A2 HU P0102187 A2 HUP0102187 A2 HU P0102187A2 HU 0102187 A HU0102187 A HU 0102187A HU P0102187 A HUP0102187 A HU P0102187A HU P0102187 A2 HUP0102187 A2 HU P0102187A2
Authority
HU
Hungary
Prior art keywords
group
compounds
dihydro
pyrimidines
formula
Prior art date
Application number
HU0102187A
Other languages
English (en)
Inventor
Argyrios Georgious Arvanitis
Robert John Chorvat
Original Assignee
Dupont Pharmaceuticals Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dupont Pharmaceuticals Co. filed Critical Dupont Pharmaceuticals Co.
Publication of HUP0102187A2 publication Critical patent/HUP0102187A2/hu
Publication of HUP0102187A3 publication Critical patent/HUP0102187A3/hu
Publication of HU228962B1 publication Critical patent/HU228962B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

A találmány szerinti vegyületek (1) vagy (2) általános képletében Ajelentése nitrogénatom vagy CR általános képletű csoport; Z jelentésenitrogénatom vagy CR általános képletű csoport; Ar jelentése adottesetben helyettesített fenil-, naftil-, piridil-, pirimidinil-,triazinil-, furanil-, tienil-, benzotienil-, benzofuranil-, 2,3-dihidro-benzofuranil-, 2,3-dihidro-benzotenil-, indanil-, 1,2-benzpiranil-, 3,4-dihidro-1,2-benzpiranil- vagy tetralinilcsoport; Rjelentése hidrogén- vagy halogénatom, alkil-, alkenil-, alkinil-,cikloalkil-, cikloalkil-alkil- vagy halogén-alkil-csoport vagy CNképletű csoport; R1 jelentése hidrogénatom, halogénatom, CN vagy SHképletű csoport vagy szerves csoport; R3 jelentése hidrogénatom, SHképletű csoport vagy szerves csoport; és R14 jelentése szervescsoport. A találmány tárgyköréhez tartoznak továbbá a fentivegyületeket tartalmazó gyógyászati készítmények, valamint evegyületek alkalmazása gyógyászati készítmények előállítására. Atalálmány szerinti készítmények pszichiátriai és ideggyógyászatirendellenességek kezelésére alkalmazhatók. Ó
HU0102187A 1996-07-24 1997-07-23 Azolo triazines, pharmaceutical compositions containing them and use of the compounds HU228962B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68604796A 1996-07-24 1996-07-24
US2329096P 1996-07-24 1996-07-24
PCT/US1997/013072 WO1998003510A1 (en) 1996-07-24 1997-07-23 AZOLO TRIAZINES AND PYRIMIDINES

Publications (3)

Publication Number Publication Date
HUP0102187A2 true HUP0102187A2 (hu) 2001-11-28
HUP0102187A3 HUP0102187A3 (en) 2002-12-28
HU228962B1 HU228962B1 (en) 2013-07-29

Family

ID=26696934

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0102187A HU228962B1 (en) 1996-07-24 1997-07-23 Azolo triazines, pharmaceutical compositions containing them and use of the compounds
HU0500549A HU229024B1 (en) 1996-07-24 1997-07-23 Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
HU0500549A HU229024B1 (en) 1996-07-24 1997-07-23 Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof

Country Status (17)

Country Link
EP (2) EP1908764A1 (hu)
KR (1) KR100548853B1 (hu)
AR (1) AR007994A1 (hu)
AT (1) ATE375344T1 (hu)
AU (1) AU747708B2 (hu)
CZ (1) CZ2005613A3 (hu)
DE (1) DE69738197T2 (hu)
DK (1) DK0915880T3 (hu)
EA (1) EA006626B1 (hu)
ES (1) ES2294800T3 (hu)
HK (1) HK1052693A1 (hu)
HU (2) HU228962B1 (hu)
LV (1) LV12292B (hu)
PT (1) PT915880E (hu)
RO (1) RO121272B1 (hu)
TW (2) TW542827B (hu)
WO (1) WO1998003510A1 (hu)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
EP0970082A2 (en) 1997-02-18 2000-01-12 Neurocrine Biosciences, Inc. Biazacyclic crf antagonists
NZ505079A (en) * 1998-01-28 2003-08-29 Du Pont Pharm Co Pyrazolotriazines and pyrazolopyrimidines useful as corticotropin releasing factor antagonists
US6613777B1 (en) 1998-03-06 2003-09-02 Chen Chen CRF antagonistic pyrazolo[4,3-b]pyridines
US6509338B1 (en) 1998-06-22 2003-01-21 Bristol-Myers Squibb Company Pyrazolo[1,5-A]triazine corticotropin releasing factor antagonists
EP1129091B1 (en) 1998-11-12 2002-10-02 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods relating thereto
WO2000027850A2 (en) 1998-11-12 2000-05-18 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods relating thereto
WO2000059907A2 (en) 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolotriazines as crf antagonists
AU4203500A (en) * 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
EA200200424A1 (ru) 1999-09-30 2002-12-26 Ньюроджен Корпорейшн Некоторые гетероциклы, замещенные алкилендиамином
AU7737900A (en) 1999-09-30 2001-04-30 Neurogen Corporation Amino substituted pyrazolo(1,5,-a)-1,5-pyrimidines and pyrazolo(1,5-a)-1,3,5-triazines
YU23802A (sh) * 1999-09-30 2004-09-03 Neurogen Corporation Određeni alkilen diamin-supstituisani pirazolo/1,5-a/-1,5- piramidini i pirazolo/1,5-a/1,3,5-triazini
CA2398956A1 (en) * 2000-02-14 2001-08-16 Japan Tobacco Inc. A pharmaceutical composition for prophylaxis or therapy of a postoperative stress
HUP0301801A2 (hu) 2000-07-14 2003-09-29 Bristol-Myers Squibb Pharma Company Imidazo[1,2-a]pirazin-származékok és az ezeket tartalmazó gyógyszerkészítmények
NZ524348A (en) * 2000-08-02 2004-07-30 Malope Company Ltd Diagnosis and treatment of non-ulcer dyspepsia based on dysfunction in the corticotropin releasing hormone (CRH) receptor and repsonse to ACTH
WO2002072202A1 (en) 2001-03-13 2002-09-19 Bristol-Myers Squibb Pharma Company 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
RU2003135424A (ru) 2001-05-14 2005-05-20 Бристол-Маерс Сквибб Фарма Компани (Us) Замещенные пиразиноны, пиридины и пиримидины в качестве лигандов кортикотропин высвобождающего фактора
US6894045B2 (en) 2001-07-12 2005-05-17 Bristol-Myers Squibb Pharma Company Tetrahydropurinones and derivatives thereof as corticotropin releasing factor receptor ligands
US7276526B2 (en) 2001-07-13 2007-10-02 Bristol-Myers Squibb Pharma Company Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands
WO2003043637A1 (en) 2001-11-20 2003-05-30 Bristol-Myers Squibb Pharma Company 3,7-dihydro-purine-2,6-dione derivatives as crf receptor ligands
AU2003217712A1 (en) 2002-03-07 2003-09-22 Smithkline Beecham Corporation Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them
CA2483159C (en) 2002-04-26 2010-08-10 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists
FR2842809A1 (fr) * 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
FR2850653A1 (fr) * 2003-02-04 2004-08-06 Univ Pasteur Derives de pyrazolotriazine, procede de preparation et utilisations
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7112585B2 (en) 2003-04-18 2006-09-26 Bristol-Myers Squibb Company Pyrimidine derivatives as corticotropin releasing factor inhibitors
US7030145B2 (en) 2003-04-18 2006-04-18 Bristol-Myers Squibb Company Pyridinyl derivatives for the treatment of depression
US7153961B2 (en) * 2003-11-25 2006-12-26 Bristol-Myers Squibb Pharma Co. Salt and crystalline form thereof of a corticotropin releasing factor receptor antagonist
US7208596B2 (en) 2003-11-25 2007-04-24 Bristol-Myers Squibb Pharma Company Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
CA2550948A1 (en) 2003-12-22 2005-07-14 Sb Pharmco Puerto Rico Inc. Crf receptor antagonists and methods relating thereto
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US20100216798A1 (en) * 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors
MX2009003125A (es) 2006-09-20 2009-05-28 Lilly Co Eli Tiazol pirazolopirimidinas como antagonistas de receptor de crf1.
CA2662000C (en) 2006-09-20 2013-01-08 Eli Lilly And Company Thiophene pyrazolopyrimidine compounds
JP5442448B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド Ｆｇｆｒインヒビターとしての二環式ヘテロ環式化合物
JP5442449B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
WO2008157302A2 (en) * 2007-06-13 2008-12-24 Research Development Foundation Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
EP2417138B1 (en) 2009-04-09 2019-11-27 Merck Sharp & Dohme Corp. Pyrazolo[1, 5-a]pyrimidine derivatives as mtor inhibitors
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
EP2264035A1 (en) * 2009-06-04 2010-12-22 Merz Pharma GmbH & Co. KGaA Glycine B antagonists
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
PT2760453T (pt) 2011-09-30 2016-08-02 Ipsen Pharma Sas Inibidores macrocíclicos da cinase lrrk2
GB201210686D0 (en) 2012-06-15 2012-08-01 Holsboermaschmeyer Neurochemie Gmbh V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
PT2925757T (pt) 2012-11-19 2018-01-09 Novartis Ag Compostos e composições para o tratamento de doenças parasitárias
US8871754B2 (en) 2012-11-19 2014-10-28 Irm Llc Compounds and compositions for the treatment of parasitic diseases
PL3808749T3 (pl) 2012-12-07 2023-07-10 Vertex Pharmaceuticals Incorporated Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
GB201310782D0 (en) 2013-06-17 2013-07-31 Max Planck Innovation Gmbh Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
JP6543252B2 (ja) 2013-12-06 2019-07-10 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ＡＴＲキナーゼ阻害剤として有用な２−アミノ−６−フルオロ−Ｎ−［５−フルオロ−ピリジン−３−イル］ピラゾロ［１，５−ａ］ピリミジン−３−カルボキサミド化合物、その調製、その異なる固体形態および放射性標識された誘導体
MX2016015874A (es) 2014-06-05 2017-03-27 Vertex Pharma Derivados radiomarcadores de un compuesto de 2-amino-6-fluoro-n-[5 -fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo.
PT3157566T (pt) 2014-06-17 2019-07-11 Vertex Pharma Método para tratamento de cancro utilizando uma combinação de inibidores chk1 e atr
PL3194405T3 (pl) 2014-09-17 2019-07-31 Oncodesign S.A. Makrocykliczne inhibitory kinazy lrrk2
RU2713937C2 (ru) 2014-11-03 2020-02-11 Байер Фарма Акциенгезельшафт Пиперидинилпиразолопиримидиноны и их применение
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
CA3000684A1 (en) 2015-09-30 2017-04-06 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna damaging agents and atr inhibitors
US20210032253A1 (en) * 2018-02-06 2021-02-04 Jiangsu Hengrui Medicine Co., Ltd. Pyrazolo[1,5-a][1,3,5]triazine-2-amine derivative, preparation method therefor and medical use thereof
JP7385658B2 (ja) 2018-10-30 2023-11-22 クロノス バイオ インコーポレイテッド Ｃｄｋ９活性を調節するための化合物、組成物、および方法
CA3188730A1 (en) 2020-08-12 2022-02-17 Christopher Barnes Methods and compositions for treating polycystic ovary syndrome
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE786611A (fr) * 1971-08-16 1973-01-22 Int Chem & Nuclear Corp Nouveaux inhibiteurs de xanthine-oxydase et leur procede de preparatio
US3910907A (en) * 1973-07-09 1975-10-07 Icn Pharmaceuticals Pyrazolo(1,5-a)-1,3,5-triazines
US3995039A (en) * 1975-05-27 1976-11-30 Merck & Co., Inc. Pyrazolo [1,5-a] [1,3,5] triazines
JPS6157587A (ja) * 1984-08-29 1986-03-24 Shionogi & Co Ltd 縮合複素環誘導体および抗潰瘍剤
US4824834A (en) * 1986-10-31 1989-04-25 Otsuka Pharmaceutical Company, Limited Pyrazolotriazine compounds
DE3722072A1 (de) * 1987-07-01 1989-01-12 Schering Ag 6,7-dihydro-pyrazolo(1,5-a)(1,3,5) triazin-2-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider und pflanzenwuchsregulierender wirkung
JP2585462B2 (ja) * 1989-10-25 1997-02-26 株式会社大塚製薬工場 ピラゾロ［１，５―ａ］ピリミジン誘導体
KR927003595A (ko) * 1990-10-09 1992-12-18 오츠카 아키히코 피리미딘 유도체, 이의 제조방법 및 안드로겐 저해제
US5484760A (en) * 1990-12-31 1996-01-16 Monsanto Company Herbicide antidotes as safeners for reducing phytotoxicity resulting from synergistic interaction between herbicides and other pesticides
KR100191774B1 (ko) * 1991-04-22 1999-06-15 오스카 아끼히꼬 피라졸로[1,5-알파] 피리미딘 유도체 및 이것을 함유하는 항염증제
US5356897A (en) * 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
DK0674641T3 (da) * 1992-12-17 1999-09-27 Pfizer Pyrrolopyrimidiner som CRF-antagonister
CN1046730C (zh) * 1994-06-21 1999-11-24 株式会社大塚制药工场 吡唑并[1,5-a]嘧啶衍生物
AU716993B2 (en) * 1995-05-12 2000-03-16 Neurogen Corporation Novel deazapurine derivatives; a new class of CRF1 specific ligands
WO1997029109A1 (en) * 1996-02-07 1997-08-14 Janssen Pharmaceutica N.V. Pyrazolopyrimidines as crf receptor antagonists

Also Published As

Publication number Publication date
EA006626B1 (ru) 2006-02-24
EA200301042A1 (ru) 2004-02-26
EP1908764A1 (en) 2008-04-09
ATE375344T1 (de) 2007-10-15
AU747708B2 (en) 2002-05-23
HUP0102187A3 (en) 2002-12-28
KR20000068010A (ko) 2000-11-25
HK1052693A1 (zh) 2003-09-26
HU228962B1 (en) 2013-07-29
DK0915880T3 (da) 2008-02-11
DE69738197T2 (de) 2008-07-17
RO121272B1 (ro) 2007-02-28
TWI238164B (en) 2005-08-21
TW542827B (en) 2003-07-21
HU0500549D0 (en) 2005-08-29
LV12292A (lv) 1999-06-20
WO1998003510A1 (en) 1998-01-29
EP0915880A1 (en) 1999-05-19
DE69738197D1 (de) 2007-11-22
HU229024B1 (en) 2013-07-29
TW200304916A (en) 2003-10-16
LV12292B (en) 1999-11-20
PT915880E (pt) 2007-12-31
AU3894297A (en) 1998-02-10
AR007994A1 (es) 1999-11-24
EP0915880B1 (en) 2007-10-10
KR100548853B1 (ko) 2006-02-02
CZ2005613A3 (cs) 2017-01-25
ES2294800T3 (es) 2008-04-01

Similar Documents

Publication Publication Date Title
HUP0102187A2 (hu) Azolo-triazinok és -pirimidinek, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
MY105438A (en) 3-aminopiperidine derivatives and related nitrogen containing heterocycles.
HUP0303037A2 (hu) Alzheimer-kór kezelésére alkalmas vegyületek és ezeket tartalmazó gyógyszerkészítmények
HUP9902471A2 (hu) Piperazin- és piperidinvegyületek, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
HUP0101999A2 (hu) 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
HUP0401889A2 (hu) 1,8-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények
GR3026231T3 (en) 3-aminopiperidine derivatives and related nitrogen containing heterocycles.
HUP0401886A2 (hu) Kemokin receptor aktivitás modulátorokként alkalmazható piperidinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUT61777A (en) Process for producing pyrimidine-nukleozides and pharmaceutical compositions containing them as active components
ATE103812T1 (de) Zusammensetzung zur behandlung von ischaemischen stoerungen in organen.
HUP9802937A2 (hu) Benzo[g]kinolin-származékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk
ATE79257T1 (de) Verwendung von tetrahydrobenz(c,d>indol-6carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden.
HUP0204354A2 (hu) Új heterociklusos vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
TW429255B (en) Pyrazine compounds having treatment of central nervous system diseases and disorders
DK0428313T3 (da) Pyrimidonderivater samt analoge til behandling af astma og visse hudlidelser
AU689808B2 (en) Dithiocarbonimide derivative, fungicidal/insecticidal/ acaricidal agent containing said derivative as active ingredient, intermediate for use in production of said derivative and process for producing said derivative from said intermediate
HUP0103166A2 (hu) Karbamát- és karbamidtartalmú készítmények, és neurotróf alkalmazásuk
KR970009570B1 (en) Intermediates of aminobenzoic acid
HUP0102112A2 (hu) Aril- (vagy heteroaril)-azolilkarbinol-származékok alkalmazása ideggyulladás kezelésére alkalmas gyógyszer előállítására
DE69925160D1 (de) Arylpiperidin- und aryl-1,2,5,6-tetrahydropyridinamid-derivate mit 5ht1a rezeptor aktivität
HUP0202647A2 (hu) Új arilalkanoilszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
ATE250027T1 (de) Azetidincarboxamidderivate zur behandlung von zns-erkrankungen
HUP0203557A2 (hu) Új amidinszármazékok, eljárás előállításukra és gyógyszerként történő alkalmazásuk
AU2178199A (en) Azetidinecarboxamide derivatives for the treatment of cns disorders
EP0301466A3 (en) Uricosuric composition